With crossover round in its pock­et, syn­thet­ic lethal­i­ty-fo­cused Cyteir Ther­a­peu­tics eyes a jump on­to Nas­daq

Cyteir Ther­a­peu­tics CEO Markus Ren­schler has his eye on the mar­ket. The Cel­gene vet pulled in an $80 mil­lion crossover round on Thurs­day to fu­el Cyteir’s lead syn­thet­ic lethal­i­ty pro­gram, and when the time is right, he’ll have the S-1 ready.

“We’re con­sid­er­ing an IPO in 2021,” Ren­schler said, adding that the tim­ing isn’t set in stone.

Un­til then, the Se­ries C should give Cyteir the flex­i­bil­i­ty to grow its team, and ad­vance its lead can­di­date — an in­hibitor of RAD51-me­di­at­ed DNA re­pair dubbed CYT-0851 — to Phase II as a monother­a­py. The small biotech is al­so plan­ning com­bi­na­tion tri­als that pair CYT-0851 with oth­er can­cer treat­ments, like chemother­a­pies and po­ten­tial­ly PARP in­hibitors.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN